Central Administration of the Neurotensin Receptor Antagonist, SR48692, Modulates Diurnal and Stress-Related Hypothalamic-Pituitary-Adrenal Activity

1997 ◽  
Vol 66 (2) ◽  
pp. 75-85 ◽  
Author(s):  
Wayne B. Rowe ◽  
Arnaud Nicot ◽  
Shakti Sharma ◽  
Danielle Gully ◽  
Claire-Dominique Walker ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Central Administration ◽  
Hypothalamic Pituitary Adrenal ◽  
Neurotensin Receptor

ChemInform Abstract: X-Ray Structural Characterization of SR 142948, a Novel Potent Synthetic Neurotensin Receptor Antagonist.

ChemInform ◽  
2010 ◽  
Vol 29 (27) ◽  
pp. no-no
Author(s):  
L. QUERE ◽  
G. LONGFILS ◽  
R. BOIGEGRAIN ◽  
B. LABEEUW ◽  
D. GULLY ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Structural Characterization ◽  
X Ray ◽  
Neurotensin Receptor

scholarly journals Hypothalamic-Pituitary-Adrenal Axis Activity of Newborn Mice Rapidly Desensitizes to Repeated Maternal Absence but Becomes Highly Responsive to Novelty

Endocrinology ◽  
2008 ◽  
Vol 149 (12) ◽  
pp. 6366-6377 ◽  
Author(s):  
L. Enthoven ◽  
M. S. Oitzl ◽  
N. Koning ◽  
M. van der Mark ◽  
E. R. de Kloet
Keyword(s):  
Glucocorticoid Receptor ◽  
Receptor Antagonist ◽  
Hpa Axis ◽  
Mineralocorticoid Receptor ◽  
Maternal Separation ◽  
Mineralocorticoid Receptor Antagonist ◽  
Newborn Mice ◽  
Hypothalamic Pituitary Adrenal ◽  
The Third ◽  
Corticosterone Response

In CD1 mice we investigated the hypothalamic-pituitary-adrenal (HPA) axis response to maternal separation for 8 h daily from postnatal d 3 to 5. At d 3 a slow separation-induced corticosterone response developed that peaked after 8 h, and the pups became responsive to stressors. On the second and third day, the response to 8 h separation rapidly attenuated, whereas the response to novelty did not, a pattern reflected by the hypothalamic c-fos mRNA response. If maternal separation and exposure to novelty were combined, then after the third such daily exposure, the sensitivity to the stressor was further enhanced. Meanwhile, basal corticosterone and ACTH levels were persistently suppressed 16 h after pups were reunited with their mothers. To explain the HPA axis desensitization after repeated separation, we found that circulating ghrelin levels increased and glucose levels decreased after all periods of maternal separation, ruling out a role of altered metabolism. Glucocorticoid feedback was not involved either because a glucocorticoid receptor antagonist amplified the corticosterone response after the first but became ineffective after the third separation. In contrast, a mineralocorticoid receptor antagonist decreased and increased corticosterone levels after the first and third period of separation, respectively. In conclusion, the newborn’s HPA axis readily desensitizes to repeated daily maternal separation, but continues to respond to novelty in a manner influenced by a central mineralocorticoid receptor- rather than glucocorticoid receptor-mediated mechanism.

SR 48692, a non-peptide neurotensin receptor antagonist, blocks the cardiovascular effects elicited by neurotensin in guinea pigs

Life Sciences ◽  
1994 ◽  
Vol 54 (7) ◽  
pp. PL95-PL100 ◽  
Author(s):  
Dino Nisato ◽  
Pierre Guiraudou ◽  
Gérard Barthélémy ◽  
Danielle Gully ◽  
G. Le Fur
Keyword(s):  
Receptor Antagonist ◽  
Guinea Pigs ◽  
Cardiovascular Effects ◽  
Neurotensin Receptor

Central Administration of Neurotensin Stimulates Hypothalamic-Pituitary-Adrenal Activity.

1992 ◽  
Vol 668 (1 The Neurobiol) ◽  
pp. 365-367 ◽  
Author(s):  
W. ROWE ◽  
V. VIAU ◽  
M. J. MEANEY ◽  
R. QUIRION
Keyword(s):  
Central Administration ◽  
Hypothalamic Pituitary Adrenal

scholarly journals Efficacy of Treatments Targeting Hypothalamic-Pituitary-Adrenal Systems for Major Depressive Disorder: A Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yudan Ding ◽  
Zirou Wei ◽  
Haohao Yan ◽  
Wenbin Guo
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Receptor Antagonist ◽  
Meta Analysis ◽  
Open Label ◽  
High Quality ◽  
Major Depressive ◽  
Hypothalamic Pituitary Adrenal ◽  
Significant Difference ◽  
Mean Differences

Abnormal hypothalamic-pituitary-adrenal (HPA) axis has been implicated in major depressive disorder (MDD). A number of studies have attempted to use HPA-modulating medications to treat depression. However, their results are inconsistent. The efficacy of these drugs for MDD remains uncertain. The aims of this meta-analysis were to determine the effect and safety profile of HPA-targeting medications for MDD. World of Science and PubMed databases were comprehensively searched up to March 2021. All randomized controlled trials (RCTs) and open-label trials exploring antiglucocorticoid and related medications in patients with depression were included. Standardized mean differences (SMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for continuous or dichotomous outcomes, respectively. In the meta-analysis, we identified 16 RCTs and seven open-label studies that included 2972 subjects. Pooling the change data that assessed the efficacy across all included HPA-targeting medications for depression showed a significant difference between interventions and controls with very small heterogeneity after influence analysis (SMD = 0.138, 95%CI = 0.052, 0.224, p = 0.002; I2 = 20.7%, p = 0.212). No obvious publication bias was observed (p = 0.127). Effectiveness remained significant in patients with MDD (SMD = 0.136, 95%CI = 0.049, 0.223, p = 0.002). Subgroup analysis showed a significant difference favoring mifepristone and vasopressin 1B (V1B) receptor antagonist treatment. Adverse events were reported by 14 studies and our analysis of high-quality studies showed a significant difference in favor of controls (RR = 1.283, 95%CI = 1.134, 1.452, p = 0). Our study suggested that patients with MDD may benefit from mifepristone and V1B receptor antagonist treatments that have tolerable side effects. HPA-based medications are promising for depression treatment. However, additional high-quality RCTs, including head-to-head trials, are needed.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/, identifier registration number: CRD42021247279

Sign in / Sign up

Export Citation Format

Share Document